MTOR and stomatitis: In the BOLERO-2 trial, indeed, the combination treatment of everolimus, an mTOR inhibitor, with examestane was limited by a high incidence of all-grade stomatitis in metastatic breast cancer women (67% of all-grade stomatitis, 33% grade 2 and 8% grade 3) [33].